Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system

Arthritis and Rheumatism

Volumn 56, Issue 3, 2007, Pages 938-948

  Katzav, Aviva ^a,b   Solodeev, Inna ^a,b   Brodsky, Ori ^c   Chapman, Joab ^a,b   Pick, Chaim G ^a   Blank, Miri ^a,b   Zhang, Wei ^d   Reichlin, Morris ^d   Shoenfeld, Yehuda ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; FLUOXETINE; HALOPERIDOL; IMMUNOGLOBULIN G; PROTEIN ANTIBODY; RIBOSOME PROTEIN; RIBOSOME PROTEIN P; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; AUTOIMMUNE DISEASE; CINGULATE GYRUS; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; FORCED SWIMMING TEST; GRIP STRENGTH; HIPPOCAMPUS; IMMOBILIZATION STRESS; LIMBIC SYSTEM; MOTOR DYSFUNCTION; MOUSE; NERVE CELL; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PASSIVE AVOIDANCE TEST; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PYRIFORM CORTEX; ROTAROD TEST; STAIRCASE TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; T MAZE ALTERNATION TEST;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AUTOIMMUNITY; BRAIN; COGNITION; DEPRESSION; DISEASE MODELS, ANIMAL; EXERTION; FEMALE; FLUOXETINE; HALOPERIDOL; LIMBIC SYSTEM; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C3H; MOTOR ACTIVITY; RIBOSOMAL PROTEINS; ROTAROD PERFORMANCE TEST;

EID: 33947175115     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22419     Document Type: Article

References (53)

1. Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. J Exp Med 1985;162:459-71.
2. Koren E, Reichlin MW, Koscec M, Fugate RD, Reichlin M. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest 1992;89:1236-41.
3. Koscec M, Koren E, Wolfson-Reichlin M, Fugate RD, Trieu E, Targoff IN, et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 1997;159:2033-41.
4. Sun KH, Tang SJ, Lin ML, Wang YS, Sun GH, Liu WT. Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture. Rheumatology (Oxford) 2001;40:750-6.
5. Sato T, Uchiumi T, Ozawa T, Kikuchi M, Nakano M, Kominami R, et al. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991;18:1681-4.
6. Reichlin M, Broyles TF, Hubscher O, James J, Lehman TA, Palermo R, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 1999;42:69-75.
7. Mahler M, Kessenbrock K, Raats J, Williams R, Fritzler MJ, Bluthner M. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med 2003;81:194-204.
8. Teh LS, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus: a reappraisal [review]. Arthritis Rheum 1994;37:307-15.
9. Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I, Shoenfeld Y, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006;13:77-83.
10. Nojima Y, Minota S, Yamada A, Takaku F, Aotsuka S, Yokohari R. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:1053-5.
11. Teh LS, Doherty DG, Williams BD. HLA-DRB genes and antiribosomal P antibodies in systemic lupus erythematosus. Br J Rheumatol 1994;33:1125-6.
12. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-71.
13. Eber T, Chapman J, Shoenfeld Y. Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus 2005;14:571-5.
14. Schneebaum AB, Singleton JD, West SG, Blodgett JK, Allen LG, Cheronis JC, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991;90:54-62.
15. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 1998;41:1819-27.
16. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
17. Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, Boki KA, Sakarellos-Daitsiotis M, Sakarellos C, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 2000;59:99-104.
18. Watanabe T, Sato T, Uchiumi T, Arakawa M. Neuropsychiatric manifestations in patients with systemic lupus erythematosus: diagnostic and predictive value of longitudinal examination of anti-ribosomal P antibody. Lupus 1996;5:178-83.
19. Press J, Palayew K, Laxer RM, Elkon K, Eddy A, Rakoff D, et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 1996;39:671-6.
20. Yoshio T, Masuyama J, Ikeda M, Tamai K, Hachiya T, Emori T, et al. Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol 1995;22:1681-7.
21. Teh LS, Bedwell AE, Isenberg DA, Gordon C, Emery P, Charles PJ, et al. Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 1992;51:489-94.
22. Van Dam A, Nossent H, de Jong J, Meilof J, ter Borg EJ, Swaak T, et al. Diagnostic value of antibodies against ribosomal phosphoproteins: a cross sectional and longitudinal study. J Rheumatol 1991;18:1026-34.
23. Derksen RH, van Dam AP, Gmelig Meyling FH, Bijlsma JW, Smeenk RJ. A prospective study on antiribosomal P proteins in two cases of familial lupus and recurrent psychosis. Ann Rheum Dis 1990;49:779-82.
24. Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002;41:1357-66.
25. Conti F, Alessandri C, Bompane D, Bombardieri M, Spinelli FR, Rusconi AC, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther 2004;6:R366-72.
26. Zhang W, Reichlin M. Production and characterization of a human monoclonal anti-idiotype to anti-ribosomal P antibodies. Clin Immunol 2005;114:130-6.
27. Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003;12:436-42.
28. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36.
29. Brey RL, Amato AA, Kagan-Hallet K, Rhine CB, Stallworth CL. Anti-intercellular adhesion molecule-1 antibody treatment prevents central and peripheral nervous system disease in autoimmune-prone mice. Lupus 1997;6:645-51.
30. Heinriches SC, Stenzel-Poore MP, Gold LH, Battenberg E, Bloom FE, Koob GF, et al. Learning impairment in transgenic mice with overexpression of corticotropin-releasing factor. Neuroscience 1996;74:303-11.
31. Petit-Demouliere B, Chenu F, Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 2005;177:245-55.
32. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997;8:523-32.
33. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238-45.
34. Gaburo N, Timoiaria C, Bueno C, Cossermelli W, Bonfa E. In-vivo effects of antiribosomal P-Protein antibodies injections into lateral ventricle of the rat-brain [abstract]. Arthritis Rheum 1995;38 Suppl 9:864.
35. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. J Psychiatr Res 1997;31:393-432.
36. Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005;11:145-55.
37. Byrum CE, Ahearn EP, Krishnan KR. A neuroanatomic model for depression. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:175-93.
38. Nugent AC, Milham MP, Bain EE, Mah L, Cannon DM, Marrett S, et al. Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage 2005. E-pub ahead of print.
39. Pause BM, Miranda A, Goder R, Aldenhoff JB, Ferstl R. Reduced olfactory performance in patients with major depression. J Psychiatr Res 2001;35:271-7.
40. McCaffrey RJ, Duff K, Solomon GS. Olfactory dysfunction discriminates probable Alzheimer's dementia from major depression: a cross-validation and extension. J Neuropsychiatry Clin Neurosci 2000;12:29-33.
41. Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005;29:627-47.
42. Mallon EB, Brockmann A, Schmid-Hempel P. Immune response inhibits associative learning in insects. Proc Biol Sci 2003;270:2471-3.
43. Zivadinov R, Zorzon M, Monti Bragadin L, Pagliaro G, Cazzato G. Olfactory loss in multiple sclerosis. J Neurol Sci 1999;168:127-30.
44. Peters JM, Hummel T, Kratzsch T, Lotsch J, Skarke C, et al. Olfactory function in mild cognitive impairment and Alzheimer's disease: an investigation using psychophysical and electrophysiological techniques. Am J Psychiatry 2003;160:1995-2002.
45. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 1983;33:943-6.
46. Kopala LC, Good KP, Morrison K, Bassett AS, Alda M, et al. Impaired olfactory identification in relatives of patients with familial schizophrenia. Am J Psychiatry 2001;158:1286-90.
47. Reichlin M. Ribosomal P antibodies and CNS lupus. Lupus 2003;12:916-8.
48. Rus H, Cudrici C, David S, Niculescu F. The complement system in central nervous system diseases. Autoimmunity 2006;39:395-402.
49. Detke MJ, Johnson J, Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 1997;5:107-12.
50. Greenwood DL, Gitlits VM, Alderuccio F, Sentry JW, Toh BH. Autoantibodies in neuropsychiatric lupus. Autoimmunity 2002;35:79-86.
51. Kowal C, DeGiorgio LA, Nakaoka T, Hetherington H, Huerta PT, Diamond B, et al. Cognition and immunity; antibody impairs memory. Immunity 2004;21:179-88.
52. Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001;10:496-9.
53. Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002;11:736-43.